Clinical Trial Search

Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale

Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Mean Change in *Delayed* Recall Score by Hopkins Verbal Learning Test-Revised (HVLT-R DR) Score — -10.6 percentage difference

Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy

Primary: Local Control — 13; 23; 2; 1 participants

Primary: The Number of Subjects Undergoing Resection Following SRS. — 11 Participants

Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029

Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants

Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR

Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05

Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants

Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004

Primary: Overall Response Rate (ORR) — 21 Participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients

Primary: Number of Patients Experiencing DLT — 0; 0; 0; 0 participants

Primary: MRI Image Data Sets — 79; 150; 290; 111 Images collected

Primary: Percent Change in Delayed Recall at 4 Months as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) — 7.0 percent change — p=<0.001

Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…

Primary: Maximum Standardized Uptake Value of 3-[18F]-FACBC — 4.5 SUVmax

Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Overall Response Rate — 71 % of pts w/complete or partial response